MAPT and Alzheimer disease: Next, we assessed the levels of tau hyperphosphorylation in the cortex at pathological phosphorylation sites observed in AD (Dave et al., 2021; Judd et al., 2023; Karikari et al., 2020; Mondragón-Rodríguez et al., 2014).